These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815 [TBL] [Abstract][Full Text] [Related]
24. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331 [TBL] [Abstract][Full Text] [Related]
25. Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules. Kim JH; Ko HY; Wang HJ; Lee H; Yun M; Kang ES Diabetes Obes Metab; 2020 Mar; 22(3):373-382. PubMed ID: 31692240 [TBL] [Abstract][Full Text] [Related]
26. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. Shao SC; Chang KC; Lin SJ; Chang SH; Hung MJ; Chan YY; Lai EC Cardiovasc Diabetol; 2021 Oct; 20(1):213. PubMed ID: 34688282 [TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world. Morieri ML; Consoli A; Sesti G; Purrello F; Avogaro A; Fadini GP; Diabetes Metab Res Rev; 2021 Jan; 37(1):e3353. PubMed ID: 32453482 [TBL] [Abstract][Full Text] [Related]
28. Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism. Op den Kamp YJM; Gemmink A; de Ligt M; Dautzenberg B; Kornips E; Jorgensen JA; Schaart G; Esterline R; Pava DA; Hoeks J; Schrauwen-Hinderling VB; Kersten S; Havekes B; Koves TR; Muoio DM; Hesselink MKC; Oscarsson J; Phielix E; Schrauwen P Mol Metab; 2022 Dec; 66():101620. PubMed ID: 36280113 [TBL] [Abstract][Full Text] [Related]
29. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248 [TBL] [Abstract][Full Text] [Related]
30. Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes. van Bommel EJM; Herrema H; Davids M; Kramer MHH; Nieuwdorp M; van Raalte DH Diabetes Metab; 2020 Apr; 46(2):164-168. PubMed ID: 31816432 [TBL] [Abstract][Full Text] [Related]
31. Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin. Furuya F; Fujita Y; Matsuo N; Minamino H; Oguri Y; Isomura N; Ikeda K; Takesue K; Li Y; Kondo A; Mano F; Inagaki N EBioMedicine; 2022 Dec; 86():104342. PubMed ID: 36423374 [TBL] [Abstract][Full Text] [Related]
32. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654 [TBL] [Abstract][Full Text] [Related]
33. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810 [TBL] [Abstract][Full Text] [Related]
34. The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis. Scholtes RA; van Raalte DH; Correa-Rotter R; Toto RD; Heerspink HJL; Cain V; Sjöström CD; Sartipy P; Stefánsson BV Diabetes Obes Metab; 2020 Apr; 22(4):549-556. PubMed ID: 31742881 [TBL] [Abstract][Full Text] [Related]